ACTG 152--TRIAL OF ZDV VERSUS DDI VERSUS DDI+AZT IN HIV INFECTED CHILDREN

ACTG 152：齐多夫定（ZDV）与 去羟肌苷（ddI）与ZDV加ddI治疗症状性HIV感染者的比较 患者中，有15名患者。 这是一场重要的审判 它直接比较了唯一获得许可的抗逆转录病毒药物 对于儿童来说，无论是单独使用还是混合使用。 这项研究在秋季结束 1995年，已经发现，AZT是不太理想的比ddI 或ddI+AZT，并帮助改变了儿童的护理标准， 艾滋病。 在我们的患者中，有两名患者因以下原因而退出研究： 遵守不佳。 这说明了一个反复出现的主题， 艾滋病毒感染对家庭、健康不良、心理压力， 父母的其他高风险行为--所有这些都是不利的， 影响家庭照顾受感染儿童的能力。

ACTG 152:, a randomized comparative trial of Zidovudine (ZDV) versus didanosine (ddI) versus ZDV plus ddI in symptomatic HIV-infected patients, has enrolled fifteen patients. This is an important trial which gives direct comparison of the only licensed antiretroviral drugs for children, both alone and in combination. This study ended in Fall of 1995, and it has been found that AZT is less optimal than either ddI or ddI+AZT, and has helped change the standard of care for children with HIV. Among our patients, two have been dropped from study because of poor compliance. This illustrates the recurrent theme of the impact of HIV-infection on families, ill health, psychological stress, and frequently other high risk behaviors by parents--all of which adversely affect the ability of the family to care for their infected children.